ReviewACS infectious diseases2024
Recent Advances in the Development of Polymyxin Antibiotics: 2010-2023.
Review in ACS infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 46 citations in OpenAlex.
- Predicting resistance evolution to guide antibiotic development.Nature reviews. Microbiology · 2026Review
- Antimicrobial Activity of a Polymyxin A-like Compound and Characterisation of the Cognate Biosynthetic Gene Cluster Within the Genome of the ProducingAntibiotics (Basel, Switzerland) · 2026Article
- Diagnostic challenges and therapeutic approach for aortic pseudoaneurysm infection withASM case reports · 2026Article
- A Cysteine-Dependent Peptide Cyclase with Broad Substrate Tolerance Enables Chemoenzymatic Synthesis of Macolacin Analogs.ACS chemical biology · 2026Article
- Metabolism-Based Biomarkers for Rapid Phenotypic Antibiotic Susceptibility Testing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Biological activity of serine-proline dipeptide to Enterobacteriaceae bacteria.Molecular biology reports · 2026Article
- Targeting carbapenem-resistant and hypervirulent Klebsiella pneumoniae: in vitro evaluation of cefepime/zidebactam, aztreonam/avibactam, imipenem/relebactam, and meropenem/vaborbactam.BMC infectious diseases · 2026Article
- Bacterial cell envelope-targeting antibiotics.Nature reviews. Microbiology · 2026Review
- Zinc-Driven Antibiotic Resistance Gene Dynamics During Vermicomposting: Insights into Co-Contamination Mitigation for Sustainable Manure Management.Antibiotics (Basel, Switzerland) · 2026Article
- A comparative study of intravenous polymyxin B and colistimethate sodium on efficacy, safety, and cost comparison in treating pulmonary infections: a retrospective cohort study.Frontiers in pharmacology · 2026Article
- Biomaterials Promote the Regression of Atherosclerotic Plaque by Regulating Cell Behavior.International journal of nanomedicine · 2026Review
- Comparative study on the wound healing effects of local versus systemic application of Polymyxin B in mice infected with multidrug-resistantFrontiers in microbiology · 2026Article
- Comparative Effectiveness of Colistin Sodium versus Polymyxin B Sulfate Against CR-GNB: A Retrospective Cohort Study.Infection and drug resistance · 2026Article
- Polymyxin resistance in Gram-negative bacteria: a comprehensive review with a focus on the role of 4-amino-4-doexy-L-arabinose.Molecular biology reports · 2025Review
- Biosurfactants as novel antibiofilm agents: mechanisms, biomedical applications, and applications in biofilm-associated infections.Archives of microbiology · 2025Review
- The Perspectives of Combining Antibiotics with Saponins-Herbal Excipients.Molecules (Basel, Switzerland) · 2025Review
- Unmasking Conformationally Adaptable Lipids as Drug Receptors.Journal of medicinal chemistry · 2025Review
- Discovery of a Novel Antimicrobial Peptide fromAntibiotics (Basel, Switzerland) · 2025Article
- The global resistance problem and the clinical antibacterial pipeline.Nature reviews. Microbiology · 2025Review
- Current Status of the Application of Antimicrobial Peptides and Their Conjugated Derivatives.Molecules (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The polymyxins are nonribosomal lipopeptides produced by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.